![Lior Shaltiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lior Shaltiel
Algemeen Directeur bij
NUREXONE BIOLOGIC INC.
Vermogen: 628 425 $ op 31-08-2026
Profiel
Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-11-2025 | 1.575.000 ( 1,67% ) | 628 425 $ | 31-08-2026 |
Actieve functies van Lior Shaltiel
| Bedrijven | Functie | Begin |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Algemeen Directeur | 01-04-2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Algemeen Directeur | 01-04-2021 |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-10-2015 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
71
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
NurExone Biologic, Inc.
 NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
